NZ551622A - Treatment of esophageal cancer with lapatinib tosylate - Google Patents
Treatment of esophageal cancer with lapatinib tosylateInfo
- Publication number
- NZ551622A NZ551622A NZ551622A NZ55162205A NZ551622A NZ 551622 A NZ551622 A NZ 551622A NZ 551622 A NZ551622 A NZ 551622A NZ 55162205 A NZ55162205 A NZ 55162205A NZ 551622 A NZ551622 A NZ 551622A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- cancer
- formula
- patients
- erbb2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57682504P | 2004-06-03 | 2004-06-03 | |
US60679004P | 2004-09-02 | 2004-09-02 | |
PCT/US2005/019053 WO2005120504A2 (en) | 2004-06-03 | 2005-06-01 | Cancer treatment method |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ551622A true NZ551622A (en) | 2010-01-29 |
Family
ID=35503647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ551622A NZ551622A (en) | 2004-06-03 | 2005-06-01 | Treatment of esophageal cancer with lapatinib tosylate |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100063074A1 (es) |
EP (1) | EP1768963A4 (es) |
JP (1) | JP2008501690A (es) |
KR (1) | KR20070030240A (es) |
AU (1) | AU2005251722B2 (es) |
BR (1) | BRPI0511754A (es) |
CA (1) | CA2569132A1 (es) |
IL (1) | IL179359A0 (es) |
MA (1) | MA28691B1 (es) |
MX (1) | MXPA06013635A (es) |
NO (1) | NO20066077L (es) |
NZ (1) | NZ551622A (es) |
RU (1) | RU2006142420A (es) |
WO (1) | WO2005120504A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010501572A (ja) * | 2006-08-22 | 2010-01-21 | コンサート ファーマシューティカルズ インコーポレイテッド | 4−アミノキナゾリン誘導体およびその使用方法 |
WO2009137714A2 (en) | 2008-05-07 | 2009-11-12 | Teva Pharmaceutical Industries Ltd. | Forms of lapatinib ditosylate and processes for preparation thereof |
US20100197915A1 (en) * | 2008-08-06 | 2010-08-05 | Leonid Metsger | Lapatinib intermediates |
EP2158912A1 (en) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
EP2158913A1 (en) | 2008-08-25 | 2010-03-03 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine |
DK2827900T3 (en) | 2012-03-23 | 2018-05-07 | Array Biopharma Inc | AMORF FIXED DISPERSION FOR USE IN THE TREATMENT OF BRAIN CANCER |
CN111032082A (zh) | 2017-04-28 | 2020-04-17 | 西雅图基因公司 | Her2阳性癌症的治疗 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9800569D0 (en) * | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
CZ299561B6 (cs) * | 2000-06-30 | 2008-09-03 | Glaxo Group Limited | Chinazolinaminový derivát a farmaceutický prostredek |
WO2002056912A2 (en) * | 2001-01-16 | 2002-07-25 | Glaxo Group Limited | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent |
JP2004002210A (ja) * | 2001-04-27 | 2004-01-08 | Takeda Chem Ind Ltd | 癌の予防・治療方法 |
JP2004002211A (ja) * | 2001-04-27 | 2004-01-08 | Takeda Chem Ind Ltd | 癌の予防・治療方法 |
DE60311788T2 (de) * | 2002-04-16 | 2007-11-22 | Astrazeneca Ab | Kombinationstherapie zur behandlung von krebs |
AU2003235470A1 (en) * | 2002-06-19 | 2004-01-06 | Smithkline Beecham Corporation | Predictive markers in cancer therapy |
CN100522955C (zh) * | 2002-08-02 | 2009-08-05 | 伊缪诺金公司 | 含有新型强效紫杉烷的细胞毒性剂及其治疗用途 |
JP2004144680A (ja) * | 2002-10-25 | 2004-05-20 | Nanko Kyo | 細胞増殖を制御する物質のスクリーニング方法、及びSp1分子等をヌクレオリン(nucleolin)分子から解離させる物質のスクリーニング方法 |
-
2005
- 2005-06-01 WO PCT/US2005/019053 patent/WO2005120504A2/en active Application Filing
- 2005-06-01 NZ NZ551622A patent/NZ551622A/en unknown
- 2005-06-01 KR KR1020067027695A patent/KR20070030240A/ko not_active Application Discontinuation
- 2005-06-01 RU RU2006142420/14A patent/RU2006142420A/ru not_active Application Discontinuation
- 2005-06-01 EP EP05784297A patent/EP1768963A4/en not_active Withdrawn
- 2005-06-01 MX MXPA06013635A patent/MXPA06013635A/es active IP Right Grant
- 2005-06-01 JP JP2007515483A patent/JP2008501690A/ja active Pending
- 2005-06-01 CA CA002569132A patent/CA2569132A1/en not_active Abandoned
- 2005-06-01 BR BRPI0511754-2A patent/BRPI0511754A/pt not_active IP Right Cessation
- 2005-06-01 US US11/569,877 patent/US20100063074A1/en not_active Abandoned
- 2005-06-01 AU AU2005251722A patent/AU2005251722B2/en not_active Ceased
-
2006
- 2006-11-16 IL IL179359A patent/IL179359A0/en unknown
- 2006-12-28 MA MA29575A patent/MA28691B1/fr unknown
- 2006-12-29 NO NO20066077A patent/NO20066077L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1768963A4 (en) | 2009-06-10 |
MA28691B1 (fr) | 2007-06-01 |
MXPA06013635A (es) | 2007-02-28 |
BRPI0511754A (pt) | 2008-01-02 |
WO2005120504A3 (en) | 2006-02-23 |
JP2008501690A (ja) | 2008-01-24 |
EP1768963A2 (en) | 2007-04-04 |
RU2006142420A (ru) | 2008-07-20 |
AU2005251722A1 (en) | 2005-12-22 |
IL179359A0 (en) | 2007-03-08 |
US20100063074A1 (en) | 2010-03-11 |
AU2005251722B2 (en) | 2009-11-12 |
CA2569132A1 (en) | 2005-12-22 |
NO20066077L (no) | 2007-01-31 |
WO2005120504A2 (en) | 2005-12-22 |
KR20070030240A (ko) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5514099B2 (ja) | プリンに基づくcdk阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用 | |
JP6911019B2 (ja) | Egfr−tki耐性を獲得した肺癌の治療薬 | |
RU2361589C2 (ru) | Способ лечения рака | |
AU2005251722B2 (en) | Cancer treatment method | |
NZ555462A (en) | Cancer treatment method | |
KR20190011770A (ko) | 암 치료 | |
US20130143834A1 (en) | Cancer Treatment Method | |
CN1989112A (zh) | 癌症治疗方法 | |
JP2018511642A (ja) | 癌を治療するための方法 | |
JP2023500889A (ja) | 非チロシン標的化キナーゼ阻害剤との併用における成長因子抗体の使用のための方法及び組成物 | |
US20080125428A1 (en) | Cancer Treatment Method | |
WO2008063853A2 (en) | Cancer treatment method | |
CN117529314A (zh) | 包含kras g12c抑制剂的药物组合及其用于治疗癌症的用途 | |
US20120035183A1 (en) | Cancer Treatment Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RENW | Renewal (renewal fees accepted) | ||
PSEA | Patent sealed |